Targeting HER2-positive breast cancer: advances and future directions
Sandra M. Swain(Georgetown University), Erika Hamilton(Sarah Cannon)
Cited by 1,048
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
HER2-Low Breast Cancer: Pathological and Clinical Landscape
|Journal of Clinical Oncology|2020|801
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
|Journal of Clinical Oncology|1997|652